- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06917313
Flash-Bread: Evaluación de la eficacia del fezolinetante en la reducción de los síntomas vasomotores en mujeres con cáncer de seno en la terapia endocrina
Un estudio aleatorizado de fase II para evaluar la eficacia del fezolinetante en la reducción de los síntomas vasomotores en mujeres con cáncer de mama en la terapia endocrina
This is a phase II, randomized, double-blinded, placebo-controlled trial designed to evaluate the efficacy of fezolinetant (45 mg a day) vs. placebo in reducing moderate to severe vasomotor symptoms (VMS) in breast cancer survivors on endocrine therapy (tamoxifen, aromatase inhibitors). The trial will proceed in a single stage, and the total of 92 participants will be randomized in 1:1 fashion to fezolinetant or placebo arm respectively.
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
This is a phase II, randomized, double-blinded, placebo-controlled trial designed to evaluate the efficacy of fezolinetant (45 mg a day) vs. placebo in reducing moderate to severe vasomotor symptoms (VMS) in breast cancer survivors on endocrine therapy (tamoxifen, aromatase inhibitors). The trial will proceed in a single stage, and the total of 92 participants will be randomized in 1:1 fashion to fezolinetant or placebo arm respectively. After the 7-14-day screening period when all the baseline, pre-treatment measures will be collected, we will record daily data on frequency and severity of VMS and calculate weekly averages of both metrics. After the 12 weeks treatment period, formal efficacy analysis will be conducted and the treatment with fezolinetant will be deemed efficacious if the final weekly average of daily frequency of VMS will be significantly reduced compared to the 'week12 - baseline' difference of the placebo arm. Upon conclusion of the formal 12-week treatment assignment, once VMS final assessment has been recorded, we will unblind the study participants to their treatment assignment. Participants will be then allowed to cross over shall they choose to do so. Due to the vast availability of safety and efficacy data in general population, we did not include interim efficacy/futility or safety analysis.
Our hypothesis is that neurokinin blockade by fezolinetant will significantly reduce vasomotor symptoms in breast cancer survivors on endocrine therapy (tamoxifen or aromatase-inhibitor) measured by mean change in frequency of moderate to severe VMS based on patient-reported data from baseline to 12-weeks.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Laura Kane
- Número de teléfono: 773-369-6904
- Correo electrónico: laura.kane@yale.edu
Ubicaciones de estudio
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06511
- Reclutamiento
- Yale University
-
Investigador principal:
- Maryam Lustberg, MD
-
Contacto:
- Carl Brown
- Número de teléfono: 203-785-4095
- Correo electrónico: carl.brown@yale.edu
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43201
- Aún no reclutando
- The Ohio State University Comprehensive Cancer Center
-
Investigador principal:
- Sagar Sardesai, MD
-
Contacto:
- Cara Dauch
- Número de teléfono: 614-814-1393
- Correo electrónico: Cara.Dauch@osumc.edu
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
Women with diagnosed, histologically confirmed, clinical stage I-III, HR+ invasive breast cancer as defined by ASCO CAP guidelines for whom adjuvant endocrine therapy would be indicated, regardless of HER2 status.
Age 18 years and older.
Currently on endocrine therapy (tamoxifen or aromatase inhibitors) as part of standard of care treatment for HR+ breast cancer. Endocrine therapy may be administered with or without ovarian suppression and/or CDK4/6 inhibitors as permitted in Section 7.1.1. Participants with HER2-positive disease are eligible and may receive concurrent HER2 monoclonal antibody therapy (e.g., trastuzumab or pertuzumab), but not HER2 antibody-drug conjugates (e.g., ado-trastuzumab emtansine T-DM1, or trastuzumab deruxtecan T-DXd).
Willing and able to provide written informed consent/assent for the trial.
Postmenopausal as defined by spontaneous amenorrhea for at least 12 consecutive months, spontaneous amenorrhea for at least 6 months with biochemical criteria or menopause (FSH > 40 IU/L), or bilateral oophorectomy for at least 6 weeks before the screening visit, or if premenopausal chemically suppressed by GnRH agonist therapy with ultrasensitive estradiol level <10.
-Premenopausal participants receiving ovarian suppression must agree to use an effective non-hormonal method of contraception during study participation and for the longest period required after the last dose of study treatment based on the contraception requirements for all anticancer therapies the participant is receiving.
o Acceptable methods of contraception include: Intrauterine device (IUD), Total hysterectomy or bilateral tubal ligation, Sexual abstinence (the reliability of abstinence must be evaluated concerning the duration of the clinical study and the participant's lifestyle), A vasectomized partner (provided the partner is the sole sexual partner of the study participant and that the vasectomized partner has received medical confirmation of the surgical success).
On endocrine therapy for a minimum of 3 months and has planned duration of 12 weeks left in the treatment regimen. Participants receiving a CDK4/6 inhibitor must have been on treatment for at least 4 weeks prior to enrollment.
Experiencing an average of seven or more moderate to severe hot flashes per day over a 7-day period as documented by Symptom Diary during the Screening Period and seeking treatment or relief for VMS.
Able to swallow oral formulation of the study agent.
Exclusion Criteria:
Participants who have a diagnosis of stage IV metastatic disease.
Receiving any other cancer treatment other than endocrine therapy. This includes chemotherapy, targeted therapies, and immunotherapy.
Receiving cytochrome CYP1A2 inhibitors.
Participants who have initiated, discontinued, or had a dose adjustment of treatment for vasomotor symptoms (prescription, over the counter, or herbal) within 28 days prior to screening.
Pregnant or lactating patients.
Known cirrhosis or active liver disease, jaundice, or elevated liver aminotransferases (ALT or AST) >2x ULN, or elevated total bilirubin, OR elevated direct bilirubin, or elevated INR, or elevated alkaline phosphatase >2x ULN.
Creatinine > 1.5 times upper limit of normal; or estimated GFR ≤ 30 mL/min per 1.73 m2 at screening.
Judgement by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Fezolinetant
Fezolinetant is an oral medication, and the first neurokinin 3 (NK3) receptor antagonist approved by the FDA in May 2023 for treatment of moderate to severe hot flashes due to menopause. It blocks the activities of the NK3 receptor which is involved in the brain's regulation of body temperature. |
45 mg tablets, administered orally once daily with or without food, to be taken throughout the entire study phase, i.e. 12 weeks |
|
Comparador de placebos: Placebo
Patients will be given placebo tablets to compare to active comparator. |
45 mg tablets, administered orally once daily with or without food, to be taken throughout the entire study phase, i.e. 12 weeks |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Frequency of moderate/severe VMS at 12 weeks of treatment with fezolinetant vs. placebo
Periodo de tiempo: Baseline to 12 weeks
|
To evaluate the mean change reduction in frequency of moderate/severe VMS at 12 weeks of treatment with fezolinetant vs. placebo in breast cancer survivors on endocrine therapy (tamoxifen or aromatase inhibitors). |
Baseline to 12 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Efficacy of fezolinetant vs. placebo in reducing the mean daily frequency of moderate/severe VMS
Periodo de tiempo: At week 4, after treatment initiation
|
To evaluate the efficacy of fezolinetant vs. placebo in reducing the mean daily frequency of moderate/severe VMS |
At week 4, after treatment initiation
|
|
Regression of mean daily frequency of moderate/severe VMS average
Periodo de tiempo: Study duration: weeks 0-12
|
To evaluate treatment activity among breast cancer survivors treated with fezolinetant vs placebo over the entire course of the study duration - measure by regression of mean daily frequency of moderate/severe VMS average every week of treatment (weeks 0-12) |
Study duration: weeks 0-12
|
|
Change in global quality of life using Functional Assessment of Cancer Therapy - Breast, Endocrine Therapy Symptoms (FACT-B ES)
Periodo de tiempo: Baseline to week 12
|
To evaluate the difference in global quality of life in breast cancer survivors treated with fezolinetant vs placebo using FACT-B ES. The total score range is 0 to 164, with higher scores indicating better quality of life |
Baseline to week 12
|
|
Differences in sleep quality using PROMIS Sleep Disturbance-Short Form 8b (PROMIS SD SF 8b)
Periodo de tiempo: Baseline, week 4 and week 12
|
To evaluate the differences in sleep quality in breast cancer survivors' treatment with fezolinetant vs placebo using patient-reported outcomes measurement information System Sleep Disturbance - Short Form 8b (PROMIS SD SF 8b. Total score is calculated by summing the items (range: 8-40), with a higher score meaning more disturbed sleep. |
Baseline, week 4 and week 12
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Maryam Lustberg, MD, Yale University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 2000037181
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .